Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News ESC 2024

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

Todd Neale

August 30, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

News Conference News AHA 2020

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

Shelley Wood

November 18, 2020

News Conference News AHA 2020

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

Todd Neale

November 16, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Conference News

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Michael O'Riordan

March 16, 2018

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

Advertisement

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content